{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021081","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.971907+00:00","generated_at":"2026-06-05T12:03:50.622931+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaxcyte FY23 net loss $402M; VAX-31 adult Phase 1/2 topline data Q3 2024; cash $1.24B","bullets":["Net loss of $402.3M for FY2023 (vs $223.5M in FY2022); cash, equivalents & investments $1.24B as of Dec 31, 2023.","VAX-31 adult Phase 1/2 study enrollment complete; topline safety, tolerability & immunogenicity data expected Q3 2024.","VAX-24 adult program Phase 3-ready following End-of-Phase 2 FDA meeting; either VAX-24 or VAX-31 to advance after VAX-31 readout.","VAX-24 infant Phase 2 enrollment nearing completion; topline data from primary series by end Q1 2025, booster by end 2025.","R&D expenses $332.3M for FY2023, up 96% YoY due to manufacturing scale-up for PCV programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021081","json":"https://secwatch.observer/filing/0000950170-24-021081.json","markdown":"https://secwatch.observer/filing/0000950170-24-021081.md","text":"https://secwatch.observer/filing/0000950170-24-021081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000095017024021081/0000950170-24-021081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000095017024021081/pcvx-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:03:50.622931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d35c8fb2f7ea4b30dbafb32a5d75733f6aee1d84","claim":"Vaxcyte, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Vaxcyte, Inc. issued a press release announcing its financial results for the quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000095017024021081/0000950170-24-021081-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}